Bone mineral density and body composition in postmenopausal women with psoriasis and psoriatic arthritis by Paulo G Pedreira et al.
RESEARCH ARTICLE Open Access
Bone mineral density and body composition in
postmenopausal women with psoriasis and
psoriatic arthritis
Paulo G Pedreira*, Marcelo M Pinheiro, Vera L Szejnfeld
Abstract
Introduction: The aim of the present study was to compare bone mineral density (BMD) and body composition
(BC) measurements as well as identify risk factors for low BMD and osteoporotic fractures in postmenopausal
women with psoriasis (Ps) and psoriatic arthritis (PsA).
Methods: A cross-sectional study was carried out in 45 PsA women, 52 Ps women and 98 healthy female controls
(HC). Clinical risk factors for low bone density and osteoporotic fracture were evaluated by a specific questionnaire.
An X-ray absorptiometry (DXA) at the lumbar spine, total femur and total body was performed on all patients. Skin
and joint outcomes were measured by specific tools (PASI, HAQ and DAS28). Morphometric vertebral fractures
were evaluated by lumbar and thoracic spine X-ray, according to Genant’s method.
Results: There were no significant differences in age, body mass index (BMI), total lean mass and bone mineral
density among the groups. However, the PsA group had a significantly higher body fat percentage (BF%) than the
Ps and HC groups. Osteoporotic fractures were more frequently observed in PsA and Ps groups than in the HC
group (P = 0.01). Recurrent falls and a longer duration of disease increased the risk of fracture (odds ratio (OR) =
18.3 and 1.08, respectively) in the PsA group (P = 0.02). Disability was the main factor related to osteoporotic
fracture in the Ps group (odds ratio (OR) = 11.1) (P = 0.02).
Conclusions: Ps and PsA patients did not present lower BMD. However, they had a higher prevalence of
osteoporotic fractures and higher risk of metabolic syndrome. Patients with a longer duration of disease, disability
and recurrent falls need preventive measures.
Introduction
Psoriasis (Ps) and psoriatic arthritis (PsA) are chronic,
immuno-mediated inflammatory diseases characterized
by abnormal expressions of keratinocytes, with actions
of interferon (IFN)-g, tumor necrosis factor (TNF)-a,
TNF-b, transforming growth factor (TGF)-b, interleukin
(IL)-1, IL-6, IL-8 and IL-17 [1-3] or activation of Th2
inflammatory response, releasing TNF-a, IL-1 and IL-6,
as well as proliferation and neovascularization of the
synovial [4,5].
According to Colucci et al., there is greater in vitro
expression of TNF-a and receptor activator of nuclear
factor-kappa ligand (RANKL) in T and B cells of the
peripheral blood as well as T cells and fibroblasts in the
synovial fluid of patients with PsA [6]. Hofbauer et al.
found an increase in serum RANKL in these patients
and significant reduction of the osteoclastogenesis after
treatment with TNF inhibitors [7]. Ng et al., evaluating
rheumatoid arthritis (RA) and PsA patients before and
after one year of anti-TNF therapy, demonstrated
increased bone density and bone formation markers in
both groups as well as reduction of bone resorption
markers [8]. Nymann et al. found a decrease of spine
BMD in patients with palmoplantar pustulosis [9]. How-
ever, this same correlation was not observed in Ps [10]
or PsA patients [11,12].
Higher release of IL-1, IL-2, IL-6, IFN-g and TNF-a is
associated with lean mass loss in patients with AIDS,
cancer, chronic obstructive pulmonary disease, kidney
failure, RA, acute myocardial infarction [13,14].
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Inflammatory cytokines activate the muscle proteolytic
system, stimulate the release of cortisol and catechola-
mines, induce lipolysis and b-oxidation, as well as higher
synthesis of very low density lipoprotein (VLDL) and tri-
glycerides and an increase of fat mass [15]. The growth
hormone (GH) and type I insulin-like growth factor
(IGF-I) increase the protein synthesis by myocites. Tous-
sirot et al. found higher serum leptin in RA patients as
well as a positive correlation with fat mass and negative
association with lean mass. However, the GH concentra-
tion was increased and IGF-I did not differ from the
control group [16]. Westhovens et al. found a significant
reduction of total body BMD and lean mass as well as
an increase of fat mass in RA patients when compared
to HC [17]. Marcora et al. demonstrated a significant
decrease of lean mass and muscle strength in men with
ankylosing spondylitis (AS) [18]. Briot et al. verified
higher spine and femur BMD and fat mass after treat-
ment with etanercept and infliximab in AS patients [19].
Saraceno and Gisondi demonstrated an increase of body
weight in Ps and PsA patients treated with etanercept,
adalimumab and infliximab [20,21].
The aim of the present study was to analyze bone
density and body composition in postmenopausal
women with psoriasis, psoriatic arthritis and in healthy
controls in order to identify risk factors for low bone
mass, fractures and changes of body composition.
Materials and methods
A cross-sectional study was carried out in 45 PsA
women, 52 Ps women and 98 HC. The diagnosis of PsA
was defined by the Classification Criteria for Psoriatic
Arthritis (CASPAR) [22]. PsA patients were in treatment
at the Rheumatology Division of Federal University of
São Paulo (UNIFESP)/Paulista School of Medicine
(EPM) and Sao Paulo Public Servants’ Hospital. Ps
patients were regularly followed-up at the UNIFESP/
EPM Dermatology Outpatient Clinic. The control group
was paired for gender, age, BMI, ethnic background and
socioeconomic class. The study was approved by the
Committee of Medical Ethics in Research of UNIFESP/
EPM. All patients agreed to participate in the study and
signed the informed consent form. Clinical risk factors
to low bone density and osteoporotic fracture were eval-
uated by a specific questionnaire based on the European
Vertebral Osteoporosis Study (EVOS) that included
details about anthropometric data, personal and medical
history, gynecological information, concomitant medica-
tions, diet, smoking and physical activity [23].
Bone mineral density measurements were performed
at lumbar spine and proximal femur, using a dual-
energy X-ray densitometer (GE-Lunar Radiation Cor-
poration, DPX MD + model, Madison, WI, USA). The
standard technical procedure was followed according to
the manufacturer’s instructions. The US National Health
and Nutrition Examination Survey (NHANES III) data-
base was adopted. The right femur was studied in all
individuals, except in those with a hip fracture, prosthe-
sis or severe arthritis on this side, in which cases the left
femur was evaluated. The coefficient of variation at our
service is 3% for the femur and 2% for the lumbar spine.
Total body densitometry was performed to evaluate
body composition (lean, fat and bone mass). The skele-
tal muscle mass index (SMMI) was calculated as the
ratio of the sum of the lean mass of the arms and legs
(kg) divided by the height squared (m2). The same cal-
culation was performed for the skeletal fat mass index
(kg/m2), considering the fat mass of the arms and legs.
Sarcopenia was defined by a SMMI below 5.45 [24]. The
coefficient of variation for the total body is 3%. In order
to differentiate the terms from BMI, the procedure
described by Giles et al. was adopted, in which a BMI
below 18.50 kg/m2 is considered underweight; a BMI
between 18.50 and 24.99 kg/m2 is the ideal weight
range; a BMI between 25 and 29.99 kg/m2 is considered
overweight; and a BMI equal to or greater than 30 kg/
m2 is obese [25]. Overfat was defined if total body fat
exceeding 41%, measured by DXA, in White women
under 60 years old or 43% for women with 60 years or
older [25,26]. Obese sarcopenia was defined as a patient
fulfilling overfat and sarcopenia criteria [25].
The Psoriasis Area Severity Index (PASI) was used to
assess the extent and severity of skin involvement in
patients with Ps and PsA [27]. The Health Assessment
Questionnaire (HAQ) was applied to determine the
degree of temporary or definitive functional impairment
[28]. Disease Activity Score 28 (DAS28) and Psoriatic
Arthritis Response Criteria (PsARC) were used to mea-
sure joint activity in PsA patients [29,30].
A thoracic and lumbar spine X-ray was performed to
identify and classify vertebral deformities or fractures,
accordingly Genant’s criteria [31].
Secondary osteoporosis, osteoarthritis that could com-
promise the bone mineral density measurements or pre-
vious diagnosis of sarcopenia were considered exclusion
criteria as well as patients with Steinbroker functional
class IV; use of insulin, statins, GH, anabolic agents,
hormonal therapy, TNF blockers or vitamin D; cognitive
impairment; cancer or active HIV infection.
Statistical analysis
The descriptive summary is presented in the form of
mean ± standard deviation. Levene’s test was used to
test the homogeneity of the sampling. The multiple
comparisons among the groups were done with analysis
of variance (ANOVA), Tukey’s post hoc test, Kruskal-
Wallis test or Mann-Whitney test. Chi-square test or
Fisher’s exact test were used for the qualitative variables.
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BMD and BC measurements were considered as depen-
dent variables. Pearson’s correlation coefficient was cal-
culated between quantitative variables that satisfied the
conditions of normality, as determined by the Kolmo-
gorov-Smirnov test. Otherwise, Spearman’s correlation
coefficient was preferred. Logistic regression models
were used for binary categorical variables (low-impact
fracture). In the multivariate regression, two models
were performed for bone density separately (spine and
femur BMD). Statistical adjustments were done for age
and weight in all tests. The level of significance was set
as P < 0.05. The analyses were performed using the Sta-
tistical Package for Social Sciences (version 15) (IBM,
Chicago, Illinois, USA).
Results
A total of 195 postmenopausal women were studied (45
PsA patients, 52 Ps patients and 98 HC), paired for age
and BMI (Table 1).
There were no significant differences in the para-
meters related to clinical characteristics of the disease,
such as duration of skin condition and PASI. However,
time of disease was two-fold greater in Ps patients.
Ungual involvement was more frequent in the PsA
group (64.4%) than the Ps group (36.5%) (P = 0.006).
PsA patients had more disability than the Ps group and
healthy controls (P < 0.001). On average, joint activity
was more severe than skin activity. Besides, there was
no significant difference in years since menopause
(Table 1). No patient had undergone hormonal replace-
ment therapy for longer than three months.
Hypertension was highly prevalent, especially among
PsA and Ps patients. The Ps group had more cases of
type 2 diabetes mellitus and dyslipidemia, without statis-
tically significant differences between groups.
PsA patients had longer duration of glicocorticoster-
oids use than Ps women (9.6 ± 22.8 and 4.8 ± 13.2
months, respectively; P = 0.14). There was no statisti-
cally significant difference in family history of osteo-
porosis or hip fracture between PsA and Ps groups as
well as recurrent falls in the last year. However, falls
were more frequent in the patients than in the control
group (P < 0.001). PsA patients had more fractures
(33.3%) than the Ps group (28.8%) (P = 0.018). Fragility
fractures were more prevalent among the Ps and PsA
groups than the HC (P = 0.001). The PsA group had
more morphometric vertebral fractures than the Ps and
control groups (P = 0.06). Dairy product intake was low,
but similar, between the three groups. Alcoholic bever-
age consumption was infrequent with no significant
Table 1 Age, anthropometric data and clinical characteristics of the women studied
PsA N = 45 Ps N = 52 Control N = 98 P
Age (years) 60.5 ± 8.7 61.4 ± 9.1 60.1 ± 8.4 0.95
Weight (kg) 69.4 ± 8.9 71.1 ± 14.2 67.8 ± 11.2 0.19
Height (m) 1.50 ± 0.7 1.50 ± 0.6 1.55 ± 0.6 0.97
BMI (kg/m2) 29.1 ± 3.6 26.6 ± 6.2 28.1 ± 4.54 0.19
Within ideal weight range *
N (%) 7 (15.6) 9 (17.3) 25 (25.5) 0.29
Overweight†
N (%) 17 (37.8) 22 (42.3) 40 (40.8) 0.9
Obese‡
N (%) 21 (46.7) 21 (40.4) 33 (33.7) 0.31
Ps Duration (years) 24.8 ± 16.2 21.8 ± 17.8 - 0.39
PsA Duration (years) 11 ± 10.5 - - -
PASI 2.2 ± 3.3 3.2 ± 3.4 - 0.22
HAQ 0.7 ± 0.5§|| 0.2 ± 0.3 0.1 ± 0.2 <0.001
DAS28 3.7 ± 1.4 - - -
PsARC
N° of swollen joints 3.2 ± 2.9 - - -
N° of painful joints 3.5 ± 3.4 - - -
Global evaluation of patient (VAS) 4 ± 2.8 - - -
Global evaluation of physician (VAS) 3.3 ± 2.4 - - -
Years since of menopause 12.7 ± 9.9 15.4 ± 10.9 12.1 ± 8.6 0.22
*BMI 18.50 - 24.99 kg/m2; †BMI 25 - 29.99 kg/m2; ‡BMI ≥ 30 kg/m2.
DAS28, disease activity score 28; HAQ, health assessment questionnaire; PASI, psoriasis area severity index; PsA, psoriatic arthritis; Ps, psoriasis; PsARC, psoriatic
arthritis response criteria; VAS, visual analogue scale.
§P < 0.001 (PsA vs. Ps).
||P < 0.001 (PsA vs. control).
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difference between groups. No patient reported the use
of illicit drugs. A current smoking habit was more fre-
quent in Ps patients (21.2%) than in PsA women (11.1%)
(P = 0.11).
Total body, spine and femur BMC and BMD measure-
ments were not different among the three (Table 2). On
the other hand, the PsA group presented almost signifi-
cantly less total lean mass (TLM) than the Ps and HC
group (P = 0.06). All groups had a large amount of total
body fat, especially patients with PsA (P = 0.04). Total
body fat (TBF) above expected values for individuals of
the same gender and age occurred in the majority of
PsA (84.4%) and Ps (65.4%) patients (P = 0.02). Overfat
was significantly more identified in the PsA group than
in the other two groups (P = 0.04), mainly with android
distribution. Moreover, all patients with PsA and sarco-
penia were obese (Table 3).
In the PsA group, spine BMD was negatively corre-
lated with years since menopause. TLM and TBF were
positively correlated with weight and BMI (Table 4). In
the Ps group, spine BMD had positive correlation with
weight and TLM. Femur BMD presented a positive
correlation with weight, BMI and TLM and inverse cor-
relation with age. TLM and TBF were positively corre-
lated with weight and BMI (Table 5).
In the PsA group, the final logistic regression model
revealed an 8% increase in the risk of fragility fracture
for each year of joint disease. Furthermore, the number
of falls increased from 2- to 18-fold the risk of fracture
in patients with recurring events. In the Ps group, there
was an 11-fold increase in the risk for each lower unit
of functional capacity (Table 6).
The final multivariate regression model showed a
reduction of 0.01 g/cm2 in spine BMD for each year
since menopause to PsA patients. However, none of the
variables studied were significantly associated with
femur BMD. In the Ps group, there was an increase of
spine and femur BMD for each one-gram increase in
Table 2 Bone density of total body, lumbar spine and
proximal femur among the women studied
PsA Ps Control P
N = 45 N = 52 N = 98
Total Body
BMC (g) 2140 ± 282 2161 ± 287 2207 ± 304 0.40
BMD (g/cm2) 1.118 ± 0.09 1.118 ± 0.1 1.117 ± 0.08 0.99
Lumbar Spine (g/cm2) 1.058 ± 0.16 1.054 ± 0.13 1.058 ± 0.15 0.98
Total Femur (g/cm2) 0.934 ± 0.13 0.922 ± 0.13 0.949 ± 0.12 0.46
BMC, bone mineral content; BMD, bone mineral density; Ps, psoriasis; PsA,
psoriatic arthritis.
Table 3 Body composition, overfat and sarcopenia
according to the body fat normality curves measured by
DXA
PsA Ps Control P
N = 45 N = 52 N = 98
TLM (kg) 35.28 ± 3.96 37.45 ± 5.32 35.93 ± 4.81 0.06
TBF (%) 46 ± 5.7* 43.8 ± 6.2 43.4 ± 5.5 0.04
Within normality (%) 15.6†‡ 34.6 37.8 0.02
Above normality (%) 84.4†‡ 65.4 62.2 0.02
Overfat (%) 86.7 || § 61.5 58.2 0.03
Sarcopenia (%) 11.1 5.8 6.1 0.50
Obesity-sarcopenia (%) 11.1 3.8 4.1 0.19
DXA, dual X-ray absorptiometry; Ps, psoriasis; PsA,: psoriatic arthritis; TBF, total
body fat; TLM, total lean mass.
*P = 0.03 (PsA vs. control).
†P < 0.05(PsA vs Ps).
‡P < 0.05 (PsA vs control).
§ P < 0.01 (PsA vs. Ps).
|| P < 0.01 (PsA vs. control).
Table 4 Correlations between anthropometric data,
clinical findings and bone density measurements in
patients with psoriatic arthritis
Vertebral Femur TLM TBF
BMD BMD
Age r* -0.05 -0.09 0.11 0.02
(P) (0.76) (0.53) (0.45) (0.86)
Weight r* 0.27 0.13 0.63 0.59
(P) (0.78) (0.39) (<0.001) (<0.001)
BMI r* 0.16 0.20 0.35 0.63
(P) (0.30) (0.17) (0.02) (<0.001)
Duration of Ps r* 0.23 0.02 0.13 -0.10
(P) (0.13) (0.88) (0.37) (0.52)
Duration of PsA r† 0.14 0.09 0.14 0.15
(P) (0.34) (0.55) (0.35) (0.34)
Duration of menopause r† -0.29 -0.14 0.07 -0.04
(P) (0.04) (0.37) (0.64) (0.79)
HAQ r† 0.04 0.01 -0.27 -0.02
(P) (0.8) (0.93) (0.08) (0.91)
PASI r† 0.08 -0.13 0.13 -0.15
(P) (0.6) (0.39) (0.38) (0.31)
DAS 28 r* -0.13 -0.19 -0.12 0.12
(P) (0.39) (0.2) (0.41) (0.43)
PsARC for swollen joints r† 0.13 -0.16 -0.01 0.02
(P) (0.41) (0.29) (0.94) (0.88)
PsARC for painful joints r† -0.13 -0.03 0.07 0.01
(P) (0.38) (0.86) (0.63) (0.93)
PsARC (VAS) - patient r† 0.05 -0.01 -0.15 0.08
(P) (0.74) (0.91) (0.32) (0.57)
PsARC (VAS) - physician r† 0.01 0.01 -0.62 0.05
(P) (0.93) (0.94) (0.69) (0.75)
TLM r* 0.19 0.15 1 -0.22
(P) (0.2) (0.33) (0.15)
TBF r* 0.11 -0.006 -0.22 1
(P) (0.48) (0.97) (0.15)
r*, Pearson’s correlation; r†, Spearman’s correlation.
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the TLM. Moreover, femur BMD was reduced by 0.005
g/cm2 for every year of increasing age.
The total hip or total femur BMD showed better per-
formance than the femoral neck in the final model of
multivariate regression in both groups (Ps and PsA).
Therefore, it was chosen as the most significant.
Discussion
Our results did not demonstrate any significant differ-
ence in spine or femur BMD in PsA or Ps patients and
healthy controls. Lean mass was similar in PsA, Ps and
HC groups, although PsA patients had a trend to a
lower lean mass than Ps patients. PsA patients had a
greater percentage of fat mass than Ps women and HC.
These results are similar to those described by Borman
et al. [11], Dheda et al. [32], Millard et al. [10] and Gri-
sar et al. [33]. However, these authors studied small,
non-homogeneous (men, pre- and postmenopausal
women) populations and had no adequate control
group.
There was also no significant difference among the
three groups when applying the 1994 World Health
Organization (WHO) criteria for osteoporosis [34]. On
the other hand, Frediani et al. found a reduction of
BMD in two-thirds of PsA patients when compared to
HC [35]. Potentially, PsA and Ps patients have higher
bone resorption markers and bone loss related to
inflammatory process and disability [33]. Similarly,
Heim et al. observed higher remodeling rates, without
trabecular bone loss, in PsA and Ps patients [36]. The
authors believe that the same hyperproliferation that
occurs in the skin may also occur in bone tissue,
thereby causing latent bone disease. Besides, they sug-
gest that Ps patients have partial resistance to the action
of vitamin D on dermic fibroblasts. If the same situation
occurs in bone tissue, this could explain the accelerated
bone remodeling. In the present study, no assessment of
bone remodeling markers or of bone biopsies was done.
Other aspects may have also played a protective role
regarding the bone density values found in the present
study, such as an overweight condition as well as
decreased smoking and lower alcohol intake. Dairy pro-
duct intake was low or inadequate in all groups, and
similar to that reported by Pinheiro et al. in the Brazi-
lian population [37]. This point demonstrates that cal-
cium intake did not play a relevant role in bone mass of
these subjects. Furthermore, few patients were taking
glucocorticosteroids or had used them for short periods
of time and in low dosages.
Although joint activity among PsA patients has been
considered moderate to severe, the skin condition was
considered mild in both groups. Moreover, dermatologi-
cal recommendations for psoriasis, such as exposure to
sunlight and ultra-violet light baths, play a beneficial
role on bone metabolism due to vitamin D synthesis
[38].
Among all the risk factors investigated, only age and
years since menopause were determinant of the BMD.
Age for femur BMD in Ps patients and years since
menopause for spine BMD in PsA postmenopausal
women are similar to those reported by Frediani et al.
[35].
Studies on body composition in inflammatory disease
are more frequent in RA or AS than is PsA patients. In
general, these studies have shown greater lean mass loss,
especially in those with higher activity of disease and
disability. The present study demonstrates that the PsA
group had a tendency to lower lean mass than Ps
women or HC.
Table 5 Correlations between anthropometric data,
clinical findings and bone density measurements in
patients with psoriasis
Vertebral Femur TLM TBF
BMD BMD
Age r* -0.21 -0.32 -0.07 0.15
(P) (0.13) (0.02) (0.64) (0.3)
Weight r† 0.29 0.45 0.72 0.76
(P) (0.04) (<0.001) (<0.001) (<0.001)
BMI r† 0.16 0.43 0.55 0.74
(P) (0.26) (<0.001) (<0.001) (<0.001)
Duration of Ps r† -0.22 0.07 0.00 -0.09
(P) (0.12) (0.96) (0.97) (0.53)
Duration of menopause r† -0.08 -0.2f -0.18 -0.06
(P) (0.55) (0.09) (0.19) (0.96)
HAQ r† -0.08 0.09 0.1 0.21
(P) (0.55) (0.48) (0.48) (0.14)
PASI r† 0.06 0.05 0.05 -0.87
(P) (0.68) (0.72) (0.73) (0.54)
TLM r† 0.28 0.56 1 0.19
(P) (0.04) (<0.001) (0.18)
TBF r† 0.06 0.14 0.19 1
(P) (0.65) (0.33) (0.18)
r*, Pearson’s correlation; r†, Spearman’s correlation.
Table 6 Final logistic regression model for low-impact
fraction among patients with psoriatic arthritis and
psoriasis
Group OR 95% CI p
Duration of PsA PsA 1.08 1.01 to 1.16 0.01
N° of falls PsA
1 to 3 2.5 0.5 to 12.4 0.02
>3 18.3 1.5 to 217.7 0.02
HAQ Ps 11.1 15.5 to 84.2 0.02
HAQ, health assessment questionnaire; Ps, psoriasis; PsA, psoriatic arthritis.
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There was a positive correlation between lean mass
and femur and spine BMD in Ps patients. In the final
multivariate regression model, TLM was the most
important aspect related to femur BMD, suggesting that
exercise and higher strength musculature could be rele-
vant strategies for increase bone mass in these patients.
This correlation was not found in PsA patients.
We observed a high percentage of total body fat in all
three groups, especially in the PsA group (P = 0.04).
Giles et al. pointed out that RA patients with an overfat
phenotype had a greater degree of joint deformity and
disability, as well as higher C-reactive protein (CRP)
levels. Also, these patients are more sarcopenic and sar-
copenic-obese [25]. Although it was not significant, in
the present study, there was a higher percentage of sarco-
penia in PsA and Ps groups. Surprisingly, all PsA patients
with sarcopenia were obese. Both Ps and PsA group had
a higher frequency of android fat distribution, which is
traditionally associated with a greater risk of cardiovascu-
lar disease, metabolic syndrome and diabetes mellitus.
Our findings are similar to those described in rheumatoid
patients [17]. A psoriasic chronic inflammatory process
causes an increase of type II insulin-like growth factor
(IGF-II), which is responsible for epidermal cell prolifera-
tion and is also implicated in atherogenesis and adipo-
genesis, as well as an increase in vascular endothelial
growth factor (VEGF), which may be associated with
angiogenesis and hyperinsulinemic states [39].
Genes associated with Ps and PsA may also be present
in patients with metabolic disorders. The psoriasis sus-
ceptibility (PSORS) loci PSORS2, PSORS3 and PSORS4
are associated with susceptibility loci to metabolic syn-
drome, type 2 diabetes mellitus, familial hyperlipidemia
and cardiovascular disease. Individual genes associated
with Ps, such as Cyclin-dependent kinase 5 regulatory
subunit associated protein 1-like 1 (CDKAL1), are also
associated with type 2 diabetes. Likewise, genes involved
with a higher risk of cardiovascular disease, such as the
isoform ApoE4 of ApoE (Apolipoprotein E), are more
prevalent in Ps patients [40]. In the present study, type
2 diabetes mellitus was more frequent in Ps patients.
This is similar to the findings described by Sommer
et al., who also found greater risk of hypertension and
dyslipidemia in these patients [41]. Furthermore, there
was a greater prevalence of hypertension in PsA and Ps
groups than HC; whereas, dyslipidemia has been more
frequent in Ps patients.
Our data suggest that both PsA and Ps patients have a
higher risk for developing metabolic syndrome and car-
diovascular disease. It is well established that Ps patients
have hyperuricemia, which could act as an aggravating
factor for metabolic syndrome. Thus, we may suppose
greater prevalence of metabolic disease in PsA and Ps
patients than in RA or AS patients.
Vertebral and non-vertebral fractures were signifi-
cantly more prevalent in PsA and Ps patients than in
the HC and Brazilian population over 40 years old [42].
Sinigaglia et al. found an association among fracture
and advanced age, disability, more prolonged disease
and more severe disease activity in RA and AS patients
[43]. Yes, the sentence is correct. In the present study,
longer disease duration and recurrent falls were predic-
tors of low-impact fractures in PsA patients, while dis-
ability was predictive of fragility fracture in Ps patients.
As bone mass measurements did not reflect the bone
status in Ps and PsA patients, the evaluation of fractures
is important. Bone neoformation may be another expla-
nation for the absence of densitometric osteoporosis in
PsA patients. However, none of our subjects have had
clinical or radiographic axial involvement.
Conclusions
PsA and Ps patients have higher risk of fragility fracture
and it seems that they also have a higher risk of devel-
oping metabolic disease, especially those patients with
longer disease duration, disability and recurrent falls.
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very low density lipoprotein; WHO: World Health Organization.
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